Kanilad (Lacosamide)

Lacosamide enhances the slow inactivation of voltage‑gated sodium channels in neurons. By stabilizing neuronal membranes and reducing repetitive firing, it lowers neuronal excitability and helps prevent the spread of seizure activity in the brain.

The specific dose of Kanilad is determined by the prescribing clinician based on the individual’s medical condition, age, renal and hepatic function, and response to therapy. Dosage titration follows clinical guidelines, but exact amounts should only be set by a qualified healthcare professional.

Safety data for lacosamide in pregnancy and lactation are limited. It should be used only if the potential therapeutic benefit outweighs any possible risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss risks and alternatives with their healthcare provider.

To request Kanilad, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Kanilad (lacosamide) differs from many traditional anticonvulsants such as carbamazepine by selectively enhancing slow inactivation of sodium channels, which may result in a distinct side‑effect profile and fewer drug‑enzyme interactions. It is often considered when patients need an alternative to agents that cause more pronounced enzyme induction or sedation.

Kanilad should be stored at ambient temperature, below 25 °C, in its original packaging. Keep the product away from moisture, heat, and direct sunlight to maintain stability. Do not store in the bathroom or near a kitchen sink.

Kanilad is taken orally, usually as a tablet that should be swallowed whole with water. It can be taken with or without food, but consistent administration with respect to meals helps maintain stable blood levels. Patients should follow the prescriber’s instructions regarding timing and any dose adjustments.

Serious adverse events include cardiac conduction abnormalities such as PR‑interval prolongation, which may lead to arrhythmias, as well as suicidal thoughts or behaviors, severe skin reactions like Stevens‑Johnson syndrome, and significant liver enzyme elevations. Prompt medical attention is required if any of these symptoms arise.

Kanilad is contraindicated in individuals with known hypersensitivity to lacosamide or any of its excipients, and in patients with severe cardiac conduction disorders (e.g., second‑ or third‑degree AV block) without a pacemaker. Caution is also advised for those with uncontrolled hepatic or renal impairment.